Spyre Therapeutics(SYRE)
Search documents
Spyre Therapeutics(SYRE) - 2021 Q1 - Quarterly Report
2021-05-10 12:33
UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37722 AEGLEA BIOTHERAPEUTICS, INC. WASHINGTON, DC 20549 FORM 10-Q (Exact Name of Registrant as Specified in its Charter) Delaware 46-4312787 (State or other jur ...
Spyre Therapeutics(SYRE) - 2020 Q4 - Annual Report
2021-03-18 12:34
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37722 AEGLEA BIOTHERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organizati ...
Aeglea BioTherapeutics (AGLE) Investor Presentation - Slideshow
2020-12-03 18:12
Reimagining The Potential Of Human Enzyme Therapeutics Corporate Overview December 2020 © Aeglea BioTherapeutics, Inc. | EXTERNAL | --- | --- | |-------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...
Spyre Therapeutics(SYRE) - 2020 Q3 - Quarterly Report
2020-11-05 13:33
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37722 AEGLEA BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 46-4312787 (State or other ...
Spyre Therapeutics(SYRE) - 2020 Q2 - Quarterly Report
2020-08-10 12:33
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37722 AEGLEA BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 46-4312787 (State or other juri ...
Spyre Therapeutics(SYRE) - 2020 Q1 - Quarterly Report
2020-05-07 12:34
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37722 AEGLEA BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 46-4312787 (State or other jur ...
Spyre Therapeutics(SYRE) - 2019 Q4 - Annual Report
2020-02-24 12:34
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37722 AEGLEA BIOTHERAPEUTICS, INC. FORM 10-K (Exact name of Registrant as specified in its charter) Delaware 46-4312787 (State or Other Jurisdiction of Incorpo ...
Aeglea Bio Therapeutics (AGLE) Investor Presentation - Slideshow
2020-01-16 18:54
Aeglea Corporate Overview JANUARY 2020 © Aeglea BioTherapeutics, Inc. | EXTERNAL | --- | --- | --- | |---------------------------------------------------------------------------------------|-------|-------| | | | | | 1 © Aeglea BioTherapeutics BioTherapeutics, Inc. \| EXTERNAL , Inc. \| EXTERNAL | | | | --- | --- | --- | --- | --- | --- | --- | --- | |-------|----------------------------------------------------------------------------------------------------------------------------|-------|-------|-------|- ...
Aeglea BioTherapeutics (AGLE) Investor Presentation - Slideshow
2019-12-04 18:39
| --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|------------------------------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | © Aeglea BioTherapeutics \| EXTERNAL DECEMBER 2019 Aeglea Corporate Overview | | | | | --- ...
Spyre Therapeutics(SYRE) - 2019 Q3 - Quarterly Report
2019-11-06 13:34
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37722 AEGLEA BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of inc ...